Zach Taiji's Wiki

Company Mentions:
- Brian Hillberdink, EVP, LEO Pharma, participates in a series of interviews for PharmExec:
- Jan van de Winkel steps down from the board of LEO Pharma to focus on his role as CEO of Genmab.
tralokinumab (ADBRY):
- The AAD publishes 2024 guidelines for monoclonal antibodies and JAK inhibitors in AD management—the first update since 2014. The FDA’s approval of ADBRY for AD in 2021 is highlighted, in addition to data from the ECZTRA trials.
- Two users on Reddit report negative experiences with ADBRY: one recently switched from DUPIXENT and the other is considering switching to RINVOQ. In discussions mentioning other failed treatments, users recommend ADBRY (1, 2, 3).
- In a YouTube video published by the Icahn School of Medicine, Dr. Emma Guttman discusses targeting IL-13 with tralokinumab to normalize type 2 inflammation in adults with moderate-to-severe AD in both early and at 2 years.
- An article in Dermatology Times about OX40 inhibition mentions ADBRY as a current FDA-approved therapy for AD.
delgocitinib:
- On X, The Lancet shares an excerpt from phase 3 of the DELTA 1 and DELTA 2 trials, highlighting the efficacy of delgocitinib in treating CHE.
- 2 Minute Medicine shares an infographic on X highlighting key results from phase 3 of the DELTA 1 and DELTA 2 trials.
- Healio publishes an article about the aforementioned trials for CHE.

In an interview on HCP Live, an investigator for the ADvocate1 and ADvocate2 studies of lebrikizumab (EBGLYSS) for AD discusses key results.
A study evaluating long-term dupilumab (DUPIXENT) for AD finds that the drug remained effective in most patients with AD up to 5 years, although ~25% of patients in the cohort study discontinued treatment because of adverse events and/or ineffectiveness.
AbbVie publishes results from its study reviewing the pharmacokinetics, safety, tolerability, and exploratory efficacy of upadacitinib (RINVOQ) in children with severe AD.
Lynk Pharmaceuticals’ phase Ib clinical trial of LNK01004 proves the ointment is well-tolerated and safe for up to four weeks in patients with AD.
cendakimab is found to be effective and generally safe for moderate to severe AD, according to a new study.
A meta-analysis comparing lebrikizumab (EBGLYSS) to dupilumab (DUPIXENT) shows similar efficacy in AD patients.
nemolizumab, an interleukin 31 receptor antagonist, is proven to be effective in patients with moderate to severe AD, after phase 3 of the ACADIA 1 and ARCADIA 2 trials.
A proposed risk-scoring system to predict dupilumab-associated ocular surface disease in patients with AD is published.
On HCP Live, Jonathan Silverberg, MD, PhD, discusses the new AHEAD recommendations for optimizing AD management.

Dr. Reddy’s Laboratories

Company Mentions:
- In an article about Citius Pharmaceuticals recently receiving FDA approval for Lymphir, Dr. Reddy’s Laboratories’ $80M sale of the drug from 2021 is mentioned.
denosumab:
- On Reddit, US patients inquire about insurance and medicare approval for Prolia (1, 2), and a Physician Assistant (PA) asks about billing for Prolia.
- 2 metastatic breast cancer patients on Reddit report positive outcomes with XGEVA injections to help improve their bone density.
- Amgen sues Samsung’s biologics unit over proposed biosimilar versions of Amgen’s Prolia and XGEVA.
COYA 302:
- The development of COYA 302 is mentioned in a news roundup of Alzheimer’s, dementia, and brain health drugs on Being Patient.
We did not find any US discussions about DRL_RI (rituximab biosimilar) or DRL_TC (tocilizumab biosimilar) take place in August.